News
BAYZF
28.97
NaN%
--
Weekly Report: what happened at BAYZF last week (0422-0426)?
Weekly Report · 19h ago
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys. Global stock indices continued an upward trend in March, with both U.S. Stocks rising by 3%. Nvidia unveiled its groundbreaking Blackwell chip at GTC 2024. The S&P 500 recorded its longest positive monthly streak since 2021.
Seeking Alpha · 4d ago
Weekly Report: what happened at BAYZF last week (0415-0419)?
Weekly Report · 04/22 10:05
ClearBridge International Value Strategy Q1 2024 Portfolio Manager Commentary
Seeking Alpha · 04/18 16:10
Bayer dethroned as Germany’s top drugmaker
Privately owned Boehringer Ingelheim surpassed German pharma giant Bayer as the country’s largest drugmaker. Bayer reported €20.8B in pharmaceutical sales in 2023. Sales from China fell below expectations as sales of Xarelto with J&J dropped below expectations.
Seeking Alpha · 04/16 16:23
Weekly Report: what happened at BAYZF last week (0408-0412)?
Weekly Report · 04/15 10:01
Ginkgo Bioworks acquires AgBiome's platform assets
Cell platform company Ginkgo Bioworks acquires AgBiome's platform assets. Financial terms of the transaction were not disclosed. The company bought Bayer's agricultural biologicals R&D facility in 2022. Gink go bioworks will buy Ag biome's biological assets.
Seeking Alpha · 04/11 11:45
Oakmark International Fund: First Calendar Quarter 2024 Commentary
The Oakmark International Fund returned 0.11% for the quarter ended March 31, compared to the benchmark, the MSCI World ex USA Index. Daimler Truck Holding was a top contributor during the quarter. Bayer is a top detractor during the same period.
Seeking Alpha · 04/10 08:00
Google, Bayer in pact for AI-powered radiology tools
Seeking Alpha · 04/09 14:27
European losers of higher financing costs - JPMorgan
J.P.Morgan analysts published a list of European companies that would suffer due to higher financing costs. According to a Global Markets Strategy report, if bond yields move further up, the market will weaken like it did last summer. The report published a basket of highly leveraged companies that could be the European losers.
Seeking Alpha · 04/08 13:41
Weekly Report: what happened at BAYZF last week (0401-0405)?
Weekly Report · 04/08 10:03
Bayer Roundup cancer jury award cut by nearly two-thirds to $550M
Bayer Roundup cancer jury award cut by nearly two-thirds to $550M. Three former users of the company's weedkiller blamed their cancers on the product. Jury awarded the three plaintiffs a total of $1.5B in November. Bayer has lost 70% of its market value since its acquisition of Monsanto.
Seeking Alpha · 04/05 20:43
Weekly Report: what happened at BAYZF last week (0325-0329)?
Weekly Report · 04/01 10:02
Weekly Report: what happened at BAYZF last week (0318-0322)?
Weekly Report · 03/25 10:04
Bayer-backed Boundless Bio sets terms for $100M IPO
Bayer-backed Boundless Bio sets terms for $100M IPO. The oncology drug developer is looking at offering 6.25M shares priced between $15 and $17. Bayer Healthcare holds a 9% stake in the company. Boundless is developing a drug for the treatment of oncogene amplified tumors.
Seeking Alpha · 03/21 16:53
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
Bayer AG announced topline results of the Phase 3 study OASIS 3 evaluating the efficacy and long-term safety of the menopause drug elinzanetant. The drug met the primary endpoint of reducing the frequency of moderate to severe vasomotor symptoms. The blood-thinning drug could have peak annual sales of more than €5 billion.
Benzinga · 03/19 13:31
Bayer to seek regulatory approval for menopause drug after third trial success
Healthcare Bayer to seek regulatory approval for menopause drug after third trial success. The drug was shown to reduce the frequency of hot flashes associated with menopausal symptoms in a third late-stage trial. Bayer will seek marketing approval for elinzanetant after the drug met the primary endpoint.
Seeking Alpha · 03/19 10:19
Weekly Report: what happened at BAYZF last week (0311-0315)?
Weekly Report · 03/18 10:03
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Bayer AG is reportedly considering using the Texas Two-Step bankruptcy approach to halt the onslaught of lawsuits in the United States. The company has been accused of causing cancer with its Roundup weedkiller. Bayer could use this tactic to halt upcoming trials and negotiate a comprehensive settlement for over 50,000 cases.
Benzinga · 03/14 19:59
1 AI Growth Stock With 54% Upside Potential
Biotech stock Recursion Pharmaceuticals, Inc. (RXRX) leads on AI-driven drug discovery. The company's shares are up over 11% year to date. Nvidia's $76 million investment in the stock is driving the stock higher. Recursion is the first biotech firm to engage with Nvidia's new generative AI platform for drug R&D.
Barchart · 03/14 07:30
More
Webull provides a variety of real-time BAYZF stock news. You can receive the latest news about Bayer A G through multiple platforms. This information may help you make smarter investment decisions.
About BAYZF
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non